Upstream Bio outlines Phase 3 plan for verekitug
Upstream Bio announced pivotal Phase 3 plans for verekitug, including a 400mg subcutaneous dose every 12 weeks and two placebo-controlled trials totaling about 1,500 patients.
Upstream Bio announced pivotal Phase 3 plans for verekitug, including a 400mg subcutaneous dose every 12 weeks and two placebo—controlled trials totaling ~1,500 patients.Key Highlights:Original SEC Filing: Upstream Bio, Inc. [ UPB ] - 8-K - Sep. 01, 2026This is an AI-powered summary. It may contain…